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Objective To study the detection rate of Clostridium difficile cytotoxin B in stool specimens from adults with
diarrhea as related to previous antimicrobial treatment.
Methods Stool specimens from 802 adult patients with diarrhea and 203 healthy controls were tested for
C. difficile cytotoxin B using a cell cytotoxicity assay. Antibiotic susceptibility testing of C. difficile was
performed with the E test.
Results Of 173 patients treated with antimicrobial medication within 5 weeks of onset of diarrhea, 60 (35%)
were positive for C. difficile cytotoxin B (group A) compared to only 41 (7%) of 629 untreated patients (group
B) and two of the 203 (1%) healthy controls. Compared to patients in group A, patients in group B possessed
characteristics not usually connected with C. difficile disease. They were generally younger (median age
40 years vs. 73 years), had been hospitalized less frequently (10% vs. 67%), had more often travelled abroad
within the previous 2 weeks (46% vs. 1%), and more often had multiple enteropathogens (41% vs. 3%).
Minimal inhibitory concentrations for vancomycin, metronidazole and fucidic acid to C. difficile isolates
ranged from 0.5 to 4 mg/L, from 0.125 to 256 mg/L and 0.25 to 4 mg/L, respectively.
Conclusions The detection rate of C. difficile cytotoxin B in patients with diarrhea, not associated with
antibiotic treatment, is comparable to that in healthy control subjects. It probably merely reflects a carrier
state without clinical significance.
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INTRODUCTION
Clostridium difficile is associated with 20–50% of cases of anti-
biotic-associated diarrhea and with almost 100% of cases of
pseudomembranous colitis. This infection constitutes an in-
creasing problem in hospitals, especially as a nosocomial disease
affecting the elderly, patients with chronic diseases and surgical
patients [1–4].
The microbiological diagnosis of C. difficile-associated diar-
rhea (CDAD) is usually based on the detection of cytotoxin B in
stool specimens or the isolation of toxigenic strains [5]. One
diagnostic dilemma is the presence of high asymptomatic
carriage rates in selected populations, especially in those that
include patients with serious underlying diseases [1, 4, 6–12]. A
positive C. difficile test might thus, in some cases, only reflect a
carrier-state without a causal relationship with the current
diarrheal disease.
Virtually all patients with CDAD have been treated with
antibiotics within 5 weeks of the onset of the disease [13, 14].
However, whether diarrhea per se, without previous antibiotic
treatment, facilitates the detection of C. difficile in feces is not
completely known.
We have recently finished a 1-year prospective study on
diarrhea in adults [15]. In the present report, we studied in
more detail all those patients found to be positive for C. difficile,
with the main purpose of comparing patients treated or not
treated with antibiotics prior to infection.
PATIENTS AND METHODS
Patients
Consecutive patients, who were admitted to the Division of
Infectious Diseases at Huddinge University Hospital, Stockholm,
Sweden, between 1 October 1996 and 30 September 1997
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because of diarrhea, were studied prospectively [15]. The
hospital serves a population of approximately 900 000 in the
southern and western parts of Stockholm. The total study
population comprised 851 adults (>15 years old), of whom
802 were screened for Clostridium difficile by culture and cyto-
toxin B. The patients delivered at least one fecal specimen for
microbiological examinations and answered a questionnaire
about recent antibiotic treatment, hospitalization, travel, date
of onset of diarrhea, and symptoms and signs, as previously
described [15]. The study was approved by the ethics committee
of the Karolinska Institute (Huddinge, Sweden).
Controls
Two hundred and three individuals with no diarrhea in the
previous 30 days were recruited during the study from people
coming for advice and immunizations before travelling abroad
[15]. Each individual delivered one fecal specimen for micro-
biological examinations. None of the control individuals had
been treated with antibiotics within the previous 5 weeks.
Laboratory examinations
Microbiological diagnosis, including identification of bacteria,
protozoa and viruses, was carried out as previously described [5,
15]. Clostridium difficile was detected by growth on cycloserine–
cefoxitin fructose agar supplemented with sodium taurocholate
(TCCFA) and by examining feces for the presence of cytotoxin
B using a McCoy cell assay in conjunction with a toxin/anti-
toxin kit (TechLab, Blacksburg, VA) [5]. Clostridium difficile-
positive stool samples were defined as those in which cytotoxin
B or toxigenic C. difficile strains were detected. Antibiotic
susceptibility testing of C. difficile was performed using the E
test (AB Biodisk, Solna, Sweden) according to the recommen-
dations of the manufacturer, as described previously [16]. Fifty-
seven strains were tested against the following antimicrobial
agents: clindamycin, fusidic acid, metronidazole, trovafloxacin,
ceftriaxone, and vancomycin. Bacteroides fragilis ATCC 25285
and Bacteroides thetaiotaomicron ATCC 29741 were used as
controls.
Statisticalmethods
Pearson’s w2 was used to evaluate differences between isolation
rates and characteristics among patient and control groups. A
Mann–Whitney U-test was used to compare ages and duration
of diarrhea in patient and control groups.
RESULTS
Characteristics of patients by previous antibiotic treatment
Of the 802 patients screened for Clostridium difficile, 173 (22%)
had been treated with antibiotics within 5 weeks of onset of
diarrhea. Of these patients, 60 (35%) were positive for C. difficile
(group A) compared to 41 of the 629 (7%) untreated patients
(group B) (P< 0.0001). Two of the 203 controls (1%) were
positive for C. difficile (P¼ 0.002) (Table 1).
In 19 C. difficile-positive patients (19%), concomitant enter-
opathogens were found: Campylobacter, six patients; Salmonella,
three patients; rotavirus, three patients; calicivirus, two patients;
enterotoxigenic Escherichia coli, two patients; Giardia, one
patient; Cryptosporidium, one patient; and Aeromonas, one
patient.
The characteristics of patients and healthy controls concern-
ing their previous antibiotic treatment are shown in Tables 1 and
2. Significant differences between C. difficile-positive patients in
groups A and B were found with regard to age, previous travel
abroad, and findings of multiple enteropathogens (Table 2).
Moreover, patients in group A had more often been recently
hospitalized and more often treated for CDAD. In total, metro-
nidazole or vancomycin were prescribed to 57 (56%) of the 101
Table1 Characteristics of 802 adult patients with diarrhea, in relation to previous antibiotic treatment, and healthy control subjects
Antibiotic treatment
within 5weeks (n¼173)
No antibiotic treatment
within 5weeks (n¼629)
Control subjectsa
P value P value (n=203)
Age, (years) median (range) 59 (19^91) <0.0001 39 (15^98) NSb 38 (17^78)
Inpatients (%) 126 (73) <0.0001 280 (45) ^
Travel abroad¼ 2weeks (%) 43 (25) <0.0001 355 (56) <0.0001 14 (7)
Multiple enteropathogens (%) 5 (3) 0.0005 74 (12) <0.0001 4 (2)
C. difficile positivec (%) 60 (35) <0.0001 41 (7) 0.002 2 (1)
Duration of diarrhea, days, median 15 NSb 14 ^
a None of the control subjects were treatedwith antibiotics within the previous 5weeks; b not significant; c presence of cytotoxin B in stools and/or isolationof
toxigenic strains.
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patients (metronidazole to 76% and vancomycin to 24% of the
cases). The duration of diarrhea was however, rather shorter in
group B than in group A patients, the median durations being
13 days and 16 days, respectively. Of the 101 patients with
CDAD, 18 (18%) experienced one or more recurrences. All
these patients belonged to the antibiotic-treated group.
Antibiotic susceptibility
The results of the antibiotic susceptibility testing are summar-
ized in Table 3. One strain was highly resistant to metronidazole
with minimal inhibitory concentration (MIC) 256 mg/L.
Decreased susceptibility to clindamycin (MICs> 2 mg/L)
was observed for 49 of the 57 (86%) tested strains.
DISCUSSION
Clostridium difficile has been found in 1–3% of healthy adults and
in 35–65% of neonates, as estimated using established methods
[6–8]. This is in agreement with the 1% carriage rate found in
the control subjects without diarrhea in the present study.
Epidemiological studies have shown that C. difficile may be
acquired by 3–30% of inpatients in different hospitals [1, 9–12],
but only a minority of these patients will develop symptoms. In
a recent study, C. difficile cytotoxin B was found in 34% of
antibiotic-treated patients without diarrhea [4] and studies on
healthy volunteers have shown colonization rates of up to 60%
after they were given antibiotics [17]. Thus, many individuals
are colonized with the micro-organism permanently or inter-
mittently, most often in connection with antimicrobial treat-
ment and hospital stay, without having diarrhea.
Many studies have determined incidence figures of C. difficile
in different patient populations and have also suggested clinical
prediction rules to optimize testing in hospitalized patients with
diarrhea [1, 4, 6–12, 18–24]. Most studies have, however,
included only those patients with clinical suspicion of CDAD
and therefore mainly patients treated with antibiotics. Barbut
et al. found an overall prevalence of C. difficile in diarrheal cases
of 9.7% when the analysis was requested by the clinician, as
opposed to 4.8% when the analysis was performed without
clinical staff prescription [22]. About 70% of both ‘cases’ and
‘controls’ had however, been treated with antibiotics during the
previous month in this study.
In the present study, C. difficile was looked for in all patients
with diarrhea, irrespective of previous antibiotic treatment and
of clinical suspicion of CDAD. Clostridium difficile was found in
13% of adult patients with diarrhea, making it the most
commonly isolated enteropathogen [15]. In patients not treated
with antibiotics within 5 weeks of onset of diarrhea, the carriage
rate was 7%, only slightly higher than the 1% carriage rate found
in healthy control subjects. Thus, a diarrheal condition per se,
which is often connected with disruption of the normal colonic
flora, does not seem to increase the yield of C. difficile in fecal
specimens. The findings of C. difficile in patients with no
previous antibiotic treatment tend to reflect a carrier state
occurring concurrently with another etiology of diarrhea. This
is supported by several factors in the present study. Besides lack
of previous antibiotic treatment, these patients generally also
possessed other characteristics usually unconnected to C. difficile
disease: younger age, previous foreign travel, presence of multi-
ple enteropathogens and no previous hospitalization. Moreover,
these patients were infrequently treated for CDAD but still had
shorter duration of diarrhea compared to the treated patients. It
must be stressed that our information of previous antibiotic
treatment only covered 5 weeks before onset of diarrhea.
However, CDAD usually develops within this time [13].
Table 2 Characteristics of101patients with positive fecal Clostridium difficile testsa in relation to previous antibiotic treatment
Antibiotic treatment
within 5weeks
(n¼60, group A)
No antibiotic treatment
within 5weeks
(n¼41, group B) P values
Age, years, median (range) 73 (22^91) 40 (16^85) <0.0001
Travel abroad¼ 2weeks (%) 6 (1) 19 (46) <0.0001
Hospitalization¼ 5weeks (%) 40 (67) 4 (10) <0.0001
Multiple enteropathogens (%) 2 (3) 17 (41) <0.0001
Antibiotic treatment ofC. difficile (%) 48 (80) 9 (22) <0.0001
Duration of diarrhea, days, median 16 13 NSb
a Presence of cytotoxin B in stools and/or isolation of toxigenic strains; b not significant.
Table 3 Antibiotic susceptibility of Clostridium difficile (E test)
MIC (mg/L)
Antibiotic Range 50% 90%
Ceftriaxone 4^256 64 256
Clindamycin 2^256 4 8
Fusidic acid 0.25^4 0.5 0.5
Metronidazole 0.125^256 0.25 0.5
Trovafloxacin 0.25^32 1 1
Vancomycin 0.5^4 1 1
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Fifty-seven of the 73 C. difficile isolates (78%) were tested for
susceptibility to six antimicrobial agents using the E test
(Table 3). All isolates were classified as susceptible to vancomy-
cin and only one strain was resistant to metronidazole, the most
common treatment alternative. The results concerning metro-
nidazole must, however, be interpreted with caution since the E
test may underestimate the MICs for this agent [16,25]. In one
study, the correlations of E test and an agar dilution method (
two dilutions) were 86.6% and 95.9% for metronidazole and
vancomycin, respectively [25]. Decreased susceptibility of
human C. difficile strains to metronidazole and vancomycin
does not seem to be a problem in clinical practice. In a recent
study from France, all 198 strains tested had MICs of 2 mg/L for
vancomycin and 97% of the strains had MICs of 4 mg/L for
metronidazole [25]. However, in a report from Spain, decreased
susceptibility to vancomycin and metronidazole was found in
10% and 14% of strains, respectively [26]. Regular surveillance
is of great importance in the detection of changes in the
antimicrobial susceptibility of C. difficile over time.
In conclusion, C. difficile was found in 35% of adult patients
with diarrhea who had been treated with antibiotics within the
previous 5 weeks, as compared to only 7% of untreated patients
with diarrhea and 1% of healthy control subjects. This indicates
that the findings of C. difficile in patients not treated with
antibiotics simply reflect the carriage state in a population
who may have diarrhea due to another cause. This further
emphasizes that the diagnosis of CDAD must be based not only
on microbiological criteria but also in combination with clinical
history and epidemiological data.
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